68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors

Not Recruiting

Trial ID: NCT01980732

Purpose

The primary objective of the study is to evaluate 68Ga-DOTA TATE PET/CT for staging and monitoring response to chemotherapy in patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.

Official Title

68Ga DOTA-TATE PET/CT in the Evaluation of Patients With Somatostatin Receptor Positive Tumors

Stanford Investigator(s)

Andrei Iagaru
Andrei Iagaru

Professor of Radiology (Nuclear Medicine)

Eligibility


Inclusion Criteria:

   - Greater than 18 years-old at the time of radiotracer administration

   - Provides written informed consent

   - Known diagnosis of NET or suspected SSTR positive tumors by 111In-Octreotide scan,
   18FDG-PET, or MRI of the abdomen when clinically indicated

   - Karnofsky score greater than 50 or ECOG Performance Status 0-2

   - Women of childbearing age must have a negative pregnancy test at screening/baseline

   - Able to remain still for duration of each imaging procedure (about one hour)

Exclusion Criteria:

   - Less than 18 years-old at the time of radiotracer administration

   - Pregnant or nursing

   - Serum creatinine >3.0 mg/dL

   - Hepatic enzyme levels more than 5 times upper limit of normal.

   - Use of any other investigational product or device within 30 days prior to dosing, or
   known requirement for any other investigational agent prior to completion of all
   scheduled study assessments.

   - Inability to lie still for the entire imaging time

   - Inability to complete the needed investigational and standard-of-care imaging
   examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)

   - Any additional medical condition, serious intercurrent illness, or other extenuating
   circumstance that, in the opinion of the Investigator, may significantly interfere
   with study compliance.

Intervention(s):

drug: 68Ga-DOTA TATE

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Krithika Rupnarayan
650-736-0959

New Trial Alerts